AbbVie executive says Juvmo could delay levodopa for early Parkinson's patients

What the FDA approved

Tavapadon is a once-daily oral selective D1/D5 receptor partial agonist [1][2][8]. The FDA approved it as Juvmo on 25 September 2026 for adults with Parkinson's disease [5][7][11]. It is the first approved dopamine agonist in that class [1][2][8].

The label adds an oral option that treats symptoms but does not slow the disease [5]. It was tested against placebo, not head-to-head against levodopa or older drugs in its class [5]. In the US, 1.1 million people live with Parkinson's and 90,000 are diagnosed each year [2]. For AbbVie, the pill is the first commercial test of its $8.7 billion acquisition of Cerevel Therapeutics [7][10]. The price and exact launch date remain undisclosed, and Citi analysts expected gradual uptake as Medicare coverage is negotiated [5][11].

The label covers use alone in early Parkinson's and as an add-on to levodopa for patients with motor fluctuations [1][2][8]. AbbVie said at approval that it expected US commercial availability in October 2026 [1][8].

Why D1/D5 selectivity matters

Existing dopamine agonists such as pramipexole and ropinirole act mainly on D2 and D3 receptors, which have been linked to impulse control disorders, excessive daytime sleepiness and lower-extremity swelling [2][5]. Juvmo targets D1 and D5 instead [2]. Hubert Fernandez, global principal investigator of TEMPO-2 and TEMPO-3, said older agonists caused sleep attacks and impulse control behaviors including gambling, shopping, eating and hypersexuality [5]. He also said D1-targeting drugs are not exempt from adverse effects, though the representation of effects of interest was much higher with D2 agonists [5].

In TEMPO-2, the most common side effects were nausea at 30%, headache at 17% and dizziness at 16% [5]. Serious treatment-emergent adverse events occurred in 4.6% of patients on the drug versus 1.3% on placebo [5].

The trial evidence

TEMPO-1 randomized 529 adults with early Parkinson's to fixed doses of 5 mg, 15 mg or placebo for 27 weeks [1]. At week 26, combined MDS-UPDRS Parts II and III scores changed by -9.7 points with 5 mg and -10.2 points with 15 mg, against +1.8 points with placebo [1]. TEMPO-2 enrolled 304 patients with early disease, and combined scores fell 10.3 points with flexible-dose Juvmo versus 1.2 points with placebo, a difference of -9.1 [1][14].

In TEMPO-3, adding Juvmo to levodopa in 507 patients increased daily ON time without troublesome dyskinesia by 1.7 hours versus 0.6 hours with placebo, a difference of 1.1 hours [1].

TEMPO-4 open-label results at 85 weeks showed 93% of patients on Juvmo plus levodopa did not need a levodopa dose increase [2]. Also, 94% of monotherapy patients never started levodopa [2]. AbbVie said about 70% of patients on standard therapy need an increase in their first year [2]. In TEMPO-1, adverse events led 18.1% of patients on the drug to stop treatment, against 4.0% on placebo, according to Healio's report on the study [5].

Commercial stakes and competition

AbbVie gained tavapadon through its $8.7 billion acquisition of Cerevel Therapeutics, completed in 2024 [7][10]. The company expects its three Parkinson's therapies, Juvmo among them, to represent more than $5 billion in peak sales [10]. Vyalev, the subcutaneous levodopa prodrug infusion approved in October 2024, generated $457 million in first-half 2026 sales [10]. Second-quarter sales rose more than 27% sequentially, and AbbVie said it is on track to become a blockbuster this year [10]. Analysts expect Juvmo revenue of $8 million this year and $70 million next year, rising to $1.4 billion by 2040, according to a Motley Fool report [9]. Levodopa has been the main Parkinson's medication for nearly 60 years and requires multiple daily doses as the disease progresses [6].

The Cerevel deal came under scrutiny after emraclidine failed two phase II schizophrenia studies [10]. AbbVie recorded a $3.5 billion impairment charge [10].

What happens next

AbbVie did not disclose a price or launch date, Reuters reported [5][11]. Citi analysts had expected a third-quarter 2026 launch and gradual uptake as Medicare coverage is negotiated [5][11]. The prescribing information includes warnings for orthostatic hypotension, hallucinations, dyskinesia and impulse control behaviors [14]. Discontinuations due to adverse events were more common with tavapadon, mostly during titration [14]. Zadikoff said in the interview that for an early patient not on levodopa, Juvmo "could provide an opportunity to potentially delay that step" [14]. Juvmo was tested against placebo, not head-to-head against levodopa or older drugs in its class [5].